Genzyme Corporation - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 208

Genzyme Corporation – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Genzyme Corporation - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Genzyme Corporation - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Genzyme Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Genzyme Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Genzyme Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Genzyme Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Genzyme Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Genzyme Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Genzyme Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Genzyme Corporation and identify potential opportunities in those areas.

List of Tables
List of Figures
Genzyme Corporation Snapshot
Genzyme Corporation Overview
Key Information
Key Facts
Genzyme Corporation – Research and Development Overview
Key Therapeutic Areas
Genzyme Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Genzyme Corporation – Pipeline Products Glance
Genzyme Corporation – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Genzyme Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Genzyme Corporation–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Genzyme Corporation – Drug Profiles
ABX-CBL
Product Description
Mechanism of Action
R&D Progress
Campath
Product Description
Mechanism of Action
R&D Progress
Clolar + Cytarabine
Product Description
Mechanism of Action
R&D Progress
Cytarabine
Product Description
Mechanism of Action
R&D Progress
Flucam
Product Description
Mechanism of Action
R&D Progress
Fludara
Product Description
Mechanism of Action
R&D Progress
Genz-112638
Product Description
Mechanism of Action
R&D Progress
Genz-644470
Product Description
Mechanism of Action
R&D Progress
Mipomersen
Product Description
Mechanism of Action
R&D Progress
Prochymal
Product Description
Mechanism of Action
R&D Progress
Ad2 + HF-1alpha + VP16
Product Description
Mechanism of Action
R&D Progress
Aminopterin
Product Description
Mechanism of Action
R&D Progress
Antithymocyte Globulin
Product Description
Mechanism of Action
R&D Progress
Apomine
Product Description
Mechanism of Action
R&D Progress
Ataluren
Product Description
Mechanism of Action
R&D Progress
CAT-192
Product Description
Mechanism of Action
R&D Progress
Chondrogen
Product Description
Mechanism of Action
R&D Progress
Clofarabine + Etoposide + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
Clolar
Product Description
Mechanism of Action
R&D Progress
Cyclosporine
Product Description
Mechanism of Action
R&D Progress
Deferitrin
Product Description
Mechanism of Action
R&D Progress
Dendritic / Tumor Cell Fusion Vaccine
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell-gp100-MART-1 Antigen Vaccine + Aldesleukin
Product Description
Mechanism of Action
R&D Progress
DENSPM
Product Description
Mechanism of Action
R&D Progress
Fetal porcine cells
Product Description
Mechanism of Action
R&D Progress
Fludara + Mitoxantrone
Product Description
Mechanism of Action
R&D Progress
G-CSF + Plerixafor + Rituxan
Product Description
Mechanism of Action
R&D Progress
Hectorol
Product Description
Mechanism of Action
R&D Progress
ILX-295501
Product Description
Mechanism of Action
R&D Progress
ILX651
Product Description
Mechanism of Action
R&D Progress
Leukine + rituximab
Product Description
Mechanism of Action
R&D Progress
Melan-A/MART-1 and gp100
Product Description
Mechanism of Action
R&D Progress
Thymoglobulin
Product Description
Mechanism of Action
R&D Progress
Trilostane + Hydrocortisone
Product Description
Mechanism of Action
R&D Progress
AAV-hAADC-2
Product Description
Mechanism of Action
R&D Progress
AAV2-sFLT01
Product Description
Mechanism of Action
R&D Progress
Acid Sphingomyelinase
Product Description
Mechanism of Action
R&D Progress
Apomine
Product Description
Mechanism of Action
R&D Progress
Clolar
Product Description
Mechanism of Action
R&D Progress
GC1008
Product Description
Mechanism of Action
R&D Progress
Gene Therapy
Product Description
Mechanism of Action
R&D Progress
Genz-644282
Product Description
Mechanism of Action
R&D Progress
GMA161
Product Description
Mechanism of Action
R&D Progress
Intoplicine
Product Description
Mechanism of Action
R&D Progress
Mozobil + Cytarabine + Daunorubicin
Product Description
Mechanism of Action
R&D Progress
aaATIII
Product Description
Mechanism of Action
R&D Progress
Genz-642347
Product Description
Mechanism of Action
R&D Progress
Genz-78132
Product Description
Mechanism of Action
R&D Progress
NsG33
Product Description
Mechanism of Action
R&D Progress
Renvela
Product Description
Mechanism of Action
R&D Progress
Drug For Amyotrophic Lateral Sclerosis
Product Description
Mechanism of Action
R&D Progress
Gen-S
Product Description
Mechanism of Action
R&D Progress
Genzyme Corporation – Pipeline Analysis
Genzyme Corporation – Pipeline Products by Therapeutic Class
Genzyme Corporation Pipeline Products By Target
Genzyme Corporation – Pipeline Products by Molecule Type
Genzyme Corporation – Recent Pipeline Updates
Genzyme Corporation - Dormant Projects
Genzyme Corporation – Company Statement
Genzyme Corporation – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 15, 2010: PTC Announces Publication Of Phase II Study Results Of Ataluren In American Journal Of Respiratory And Critical Care Medicine
Oct 20, 2010: Genzyme Announces Phase III Trial Results Of Clolar In Adult Acute Myeloid Leukemia
Oct 15, 2010: PTC Presents Ataluren Phase II Data In Nonsense Mutation Duchenne/Becker Muscular Dystrophy At World Muscle Society Congress
Oct 15, 2010: PTC Presents Ataluren Phase II Data In Nonsense Mutation Duchenne/Becker Muscular Dystrophy At World Muscle Society Congress
Oct 14, 2010: Genzyme Reports Five-Year Patient Data Of Alemtuzumab From Phase II Multiple Sclerosis Trial
Oct 07, 2010: Genzyme To Present Five-Year Patient Follow-Up Data From Alemtuzumab Phase II Multiple Sclerosis Trial At ECTRIMS 2010
Sep 20, 2010: Genzyme's Synvisc Receives Japanese Approval For Treatment of Osteoarthritis Of Knee
Sep 01, 2010: Genzyme And Isis Report Positive Data From Mipomersen Phase III Trial In heFH Patients
Aug 23, 2010: Genzyme Announces Publication Of Phase II Trial Results Of Eliglustat Tartrate For Gaucher Disease In Journal Blood
Aug 04, 2010: Genzyme And Isis Report Results Of Two Phase III Trials Of Mipomersen
Financial Deals Landscape
Genzyme Corporation, Deals Volume Summary, 2004 to YTD 2010
Genzyme Corporation, Deals Summary By Region, 2004 to YTD 2010
Genzyme Corporation, Deals Summary, 2004 to YTD 2010
Genzyme Corporation Detailed Deal Summary
Asset Purchase
Genzyme To Acquire Leukine Manufacturing Facility From Bayer HealthCare
Acquisition
Genzyme Acquires Minority Stake In EXACT Sciences
Genzyme Corporation Completes Acquisition Of Bioenvision
Genzyme Acquires Anormed
Genzyme Acquires Surgi.B From Brennen Medical
Genzyme Acquires Verigen
Genzyme Acquires Equal Diagnostics
Genzyme Acquires Bone Care International
Genzyme Acquires ILEX Oncology
Genzyme Acquires Alfigen
Venture Financing
KaloBios Pharmaceuticals Secures $32 Million In Series D Financing
Proteostasis Therapeutics Secures $45 Million In Series A Financing
TcLand Expression Secures $12.04 Million In Series A Financing
Sirtris Pharmaceuticals Secures $22 Million In Series C Financing
Equity Offering
EXACT Sciences Completes Private Placement Of $6 Million
to-BBB technologies Enters Into Research Agreement With Genzyme
ERGOMED Signs An Agreement With Genzyme
Genzyme Enters Into Agreement With International Center for Genetic Engineering and Biotechnology
Genzyme Enters Into Agreement With Osiris Therapeutics
Genzyme Signs A Research Agreement With Asterion
Genzyme And Medicines for Malaria Venture Enters Into Agreement With Advinus Therapeutics
Genzyme Genetics Signs An Agreement With DxS
C. R. Bard Signs Licensing Agreement With Genzyme
Fovea Pharmaceuticals Enters Into Research Agreement With Genzyme
Genzyme Enters Into Agreement With Sunway Biotech
Osiris Therapeutics Enters Into An Agreement With Genzyme
Genzyme Enters Co-Development Agreement With Oswaldo Cruz Foundation
Genzyme Enters Into Agreement With PTC Therapeutics
Ceregene Enters Into Agreement With Genzyme
Mentor Enters Into An Agreement With Genzyme
Medicines For Malaria Enters Into Co-Development Agreement With Genzyme And Broad Institute
Angiotech Pharmaceuticals Forms Joint Venture With Genzyme
De Novo Pharmaceuticals Enters Into Collaboration With Genzyme
Macrozyme Enters Into Collaboration With Genzyme
Genzyme Enters Into Worldwide Agreement With RenaMed Biologics
ViaCell Enters Into Collaboration With Genzyme
Genzyme Enters Into Co-Development Agreement With Applied Genetic Technologies
Tm Bioscience Forms Collaboration With Genzyme
Mirus Bio Enters Into Research Agreement With Genzyme
Medtronic Signs Joint Venture Agreement With Genzyme
Dyax Terminates Joint Venture Agreement With Genzyme
Genzyme Terminates Co-Development Agreement With RenaMed Biologics
Licensing Agreements
Genzyme Enters Into Licensing Agreement With Targeted Genetics
Isis Pharmaceuticals Enters Into Licensing Agreement With Genzyme
Genzyme Enters Into Licensing Agreement With Moffitt Cancer Center
Callisto Pharmaceuticals Amends Its Licensing Agreement with Genzyme
Crucell Enters Into Licensing Agreement With Genzyme
DiagnoCure Enters Into License Agreement With Genzyme
Genzyme Enters Into Licensing Agreement With University of California
Allergan Amends Licensing Agreement With Genzyme
Santhera Pharmaceuticals Enters Into Option And License Agreement With Genzyme
Genzyme Enters Into Licensing Agreement With Genetic Technologies
Valentis Expands Its Licensing Agreement With Genzyme
Nicholas Piramal India Enters Into A Licensing Agreement With Genzyme
Dyax Enters Into Licensing Agreement With Genzyme
Genzyme Enters Into Licensing Agreement With Peptimmune
AnorMED Enters Into Licensing Agreement With NeoRx
Genzyme Enters Into A Licensing Agreement With Procter & Gamble Pharmaceuticals
Shire Enters Into Licensing Agreement With AnorMED
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Defense Robotics - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• International Military and Government Helicopter Survey
• Aerospace and Defence Industry - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Charter Schools - Global Outlook